SCHEMBL2632661

SCHEMBL2632661

CCC(=O)c1ccnn1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
HTT P42858 1/20 0.50
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46
ALDH1A1 P00352 3/20 0.45
HSD17B10 Q99714 2/20 0.45
TSHR P16473 1/20 0.45
GPR52 Q9Y2T5 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
NAMPT P43490 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.43
TAS1R1 Q7RTX1 1/20 0.43
TAS1R2 Q8TE23 1/20 0.43
KDM4E B2RXH2 2/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16865849 0.84 KMT2A (0.51) KMT2AL3MBTL1HTTRAB9ANPC1
Hydrochloric Acid SCHEMBL23354382 0.81 KMT2A (0.49) KMT2AL3MBTL1HTTRAB9ANPC1
SCHEMBL27278396 0.79 HTT (0.67) KMT2AL3MBTL1HTTRAB9ANPC1
SCHEMBL335332 0.77
SCHEMBL262323 0.77
SCHEMBL23354197 0.77 KMT2A (0.53) KMT2AL3MBTL1HTTRAB9ANPC1
SCHEMBL343502 0.76 GAA (0.59) KMT2AL3MBTL1HTTRAB9ANPC1
SCHEMBL3410537 0.76 KMT2A (0.69) KMT2AL3MBTL1HTTRAB9ANPC1
SCHEMBL25856053 0.76 KMT2A (0.34) KMT2AL3MBTL1HTTRAB9ANPC1
SCHEMBL20488237 0.75 KMT2A (0.48) KMT2AL3MBTL1HTTRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
WO-2022266015-A1 FUSED HETEROARYL COMPOUNDS USEFUL AS ANTICANCER AGENTS KUMQUAT BIOSCIENCES INC. (US) 2022-12-22 WO disclosed
US-9963478-B2 Mannose derivatives for treating bacterial infections VERTEX PHARMACEUTICALS INCORPORATED (US) 2018-05-08 US disclosed
CN-104583212-A Pyrimidinone derivatives as antimalarial agents SANOFI SA 2015-04-29 CN disclosed
US-8163763-B2 Pyrimidine compounds, compositions and methods of use GENENTECH, INC. (US) 2012-04-24 US disclosed
US-20110269700-A1 GLUCOSIDE DERIVATIVES AND USES THEREOF NOVARTIS AG 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269700-A1 GLUCOSIDE DERIVATIVES AND USES THEREOF SLC5A1, UGGT1, SLC5A2 KMT2A 4088/4885L3MBTL1 4231/4885HTT 1675/4885
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF TP53, HRAS, KRAS KMT2A 2941/4885L3MBTL1 1892/4885HTT 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.